University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Faculty Publications from Nebraska Center for
Materials and Nanoscience

Materials and Nanoscience, Nebraska Center
for (NCMN)

2020

Rod-shape theranostic nanoparticles facilitate antiretroviral drug
biodistribution and activity in human immunodeficiency virus
susceptible cells and tissues
Bhavesh D. Kevadiya
Brendan Ottemann
Insiya Z. Mukadam
Laura Castellanos
Kristen Sikora

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unl.edu/cmrafacpub
Part of the Atomic, Molecular and Optical Physics Commons, Condensed Matter Physics Commons,
Engineering Physics Commons, and the Other Physics Commons
This Article is brought to you for free and open access by the Materials and Nanoscience, Nebraska Center for
(NCMN) at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty
Publications from Nebraska Center for Materials and Nanoscience by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.

Authors
Bhavesh D. Kevadiya, Brendan Ottemann, Insiya Z. Mukadam, Laura Castellanos, Kristen Sikora, James R.
Hilaire, Jatin Machhi, Jonathan Herskovitz, Dhruvkumar Soni, Mahmudul Hasan, Wenting Zhang,
Anandakumar Sarella, Jered Garrison, JoEllyn McMillan, Benson Edagwa, R. Lee Mosley, Richard W.
Vachet, and Howard E. Gendelman

Theranostics 2020, Vol. 10, Issue 2

Ivyspring

International Publisher

630

Theranostics
2020; 10(2): 630-656. doi: 10.7150/thno.39847

Research Paper

Rod-shape theranostic nanoparticles facilitate
antiretroviral drug biodistribution and activity in human
immunodeficiency virus susceptible cells and tissues
Bhavesh D. Kevadiya1, Brendan Ottemann1, Insiya Z. Mukadam2, Laura Castellanos3, Kristen Sikora3,
James R. Hilaire1, Jatin Machhi1, Jonathan Herskovitz1,4, Dhruvkumar Soni2, Mahmudul Hasan2, Wenting
Zhang2, Sarella Anandakumar5, Jered Garrison2, JoEllyn McMillan1, Benson Edagwa1, R. Lee Mosley1,
Richard W. Vachet3 and Howard E. Gendelman1,2,4
1.
2.
3.
4.
5.

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, USA
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, USA
Department of Chemistry, University of Massachusetts, Amherst, MA, USA
Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, NE, USA
Nebraska Center for Materials and Nanoscience, University of Nebraska-Lincoln, NE, USA

 Corresponding author: Howard E. Gendelman, M.D., Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center,
Omaha, NE 68198; phone 402 559 8920; FAX: 402 559 3744; Email: hegendel@unmc.edu
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.09.01; Accepted: 2019.10.06; Published: 2020.01.01

Abstract
Human immunodeficiency virus theranostics facilitates the development of long acting (LA) antiretroviral
drugs (ARVs) by defining drug-particle cell depots. Optimal drug formulations are made possible based on
precise particle composition, structure, shape and size. Through the creation of rod-shaped particles of
defined sizes reflective of native LA drugs, theranostic probes can be deployed to measure particle-cell
and tissue biodistribution, antiretroviral activities and drug retention.
Methods: Herein, we created multimodal rilpivirine (RPV) 177lutetium labeled bismuth sulfide nanorods
(177LuBSNRs) then evaluated their structure, morphology, configuration, chemical composition, biological
responses and adverse reactions. Particle biodistribution was analyzed by single photon emission
computed tomography (SPECT/CT) and laser ablation inductively coupled plasma mass spectrometry
(LA-ICP-MS) imaging.
Results: Nanoformulated RPV and BSNRs-RPV particles showed comparable physicochemical and cell
biological properties. Drug-particle pharmacokinetics (PK) and biodistribution in lymphoid tissue
macrophages proved equivalent, one with the other. Rapid particle uptake and tissue distribution were
observed, without adverse reactions, in primary blood-derived and tissue macrophages. The latter was
seen within the marginal zones of spleen.
Conclusions: These data, taken together, support the use of 177LuBSNRs as theranostic probes as a
rapid assessment tool for PK LA ARV measurements.
Key words: Long acting antiretroviral therapy, Laser ablation inductively coupled plasma mass spectrometry,
Single photon emission computed tomography, Drug biodistribution, Multimodal imaging

Introduction
Current management of human immunodeficiency virus type one (HIV-1) infection has
transformed clinical outcomes from a life-threatening
disease to a chronic manageable medical condition.[1,
2] Nonetheless, required lifelong daily dosing of

combination antiretroviral therapy (ART) has
limitations for regimen adherence and in pill
fatigue.[3, 4] Recently the prospect of broad
dissemination of antiretroviral drugs (ARVs) to
virus-infected and susceptible people has led to the
http://www.thno.org
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notion that improved therapeutic regimen adherence
could eliminate the acquired immunodeficiency
(AIDS)
epidemic.[5,
6]
However,
complete
elimination requires more effective clinical outcomes
for both pre-exposure prophylaxis and treatment
regimens.[7] Moreover, recent studies suggest that
total HIV-1 elimination could be achieved by excision
of integrated HIV-1 DNA or through the use of
broadly neutralizing antibodies. However, these
treatments are years from human use, which
underscores the immediate need for better
antiretroviral regimens.[8-11]
One pathway forward to affect patient treatment
outcomes
is
by
long-acting
(LA)
ARV
injectables.[12-15] These new deliverables hold
considerable promise towards improving patient
adherence and affecting reduction of viral reservoirs.
This is made possible by changing pharmacological
management to affect drug efficacy. Such approaches
eliminate the requirements for lifelong daily pills.
Nonetheless, a number of challenges exist to
implement such regimens. These include, but are not
limited to, required dosing volumes, frequencies of
injection, untoward side effects, and maintenance of
antiretroviral efficacy.[16-18] Even more importantly,
only two LA ARVs are currently in the pipeline.[12]
Such limitations in drug choices preclude alternative
therapies when required by either developed
resistance mutations or adverse events. To these ends,
our laboratories have employed ARV chemical
modifications to create novel LA prodrug libraries
designed to extend drug half-life and enhance
bioavailability.[13, 14, 19-22] Notwithstanding, these
novel prodrugs ensure drug penetration into
“putative” viral reservoirs and sustain maximal
antiretroviral activities.[15, 23] We posit that development can be accelerated by modeling drug delivery,
pharmacokinetics (PK), and biodistribution (BD).
HIV theranostics, if appropriately implemented,
would accelerate the development of LA ARVs by
predicting real-time drug biodistribution and
potency.[24, 25] The creation of theranostic probes
would serve to speed bench to bedside research in the
development of the most effective LA ARV
nanoformulations. Thus, we sought to engineer
nanoparticles that mimicked LA ARV particles in
shape and morphology while optimizing size and
design. To these ends, the use of bismuth (Bi) and
sulfur (S) proved to be a natural choice as the
components add a heavy metal detector, proven
bioimaging capabilities and rapid oxidative
decompositions required for human translation.[26,
27] Intrinsically-radiolabeled 177lutetium (177Lu)
bismuth sulfide nanorods (177LuBSNRs) were created
as multimodal imaging particles to serve as probes for
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drug biodistribution of LA nanoformulated rilpivirine
(NRPV). RPV, a non-nucleoside reverse transcriptase
inhibitor (NNRTI), was chosen as a model for other
LA ARVs based on its highly hydrophobic and
protein binding properties as well as extended plasma
half-life.[24] We used 177LuBSNRs as imaging probes
to mirror the structure, morphology, biological
properties and atomic configuration of the
177LuBSNRs
of LA NRPV. Biodistribution of
177Lu/BSNRs/RPV
into
lymphoid
tissue
macrophages was demonstrated in Balb/c mice using
single photon emission computed tomography
(SPECT) and laser ablation inductively coupled
plasma mass spectrometry (LA-ICP-MS). The
BSNRs/RPV
particles
demonstrated
potent
antiretroviral activities in cell-based assays. These
data, taken together, demonstrate that these
multimodal particles can be effective imaging probes
for assessing LA NRPV biodistribution. The work
demonstrates their translational application for
determining LA ARV PK and pharmacodynamics
(PD).

Results
Creation of 177LuBSNRs particles
Chelator-free, 177LuBSNRs nanocrystals were
first synthesized by solvothermal precipitation of
bismuth neodecanoate and thioacetamide in the
presence of oleic acid, oleylamine and ethanol. The
crystallinity, monodispersity, shape, and size of the
particles were monitored during synthesis, and
optimized by varying time intervals and molar ratios
of bismuth and thiol precursors. During synthesis,
oleyl amine served as ligand and solvent with
bismuth.[28] The prepared 177LuBSNRs were
dispersed in cyclohexane and converted to a freely
dispersed hydrophilic solution in the aqueous phase.
To ensure biocompatibility, the hydrophobic
177LuBSNRs particles were coated with biocompatible
lipids. Lipid coated 177LuBSNRs were synthesized by
a simple film hydration technique to make uniform
preparations more appropriate for biological use than
uncoated hydrophobic particles. L-α-phosphatidylcholine and DSPE-PEG2000 were used to functionalize
the particles. An experimental outline is presented in
the schematics diagram (Supplementary Figure S1
top panel). The plain, non-lipid coated and
non-radiolabeled BSNRs were characterized by
various techniques. Low power TEM revealed that the
plain non-radiolabeled BSNRs nanocrystals had a rod
shape, of approximately 12 nm in diameter by 70 nm
in length (Figure 1A). High resolution (HR)-TEM
images (Figure 1B-C) show the lattice fringes with
spacings of 0.356 and 0.194 nm. These are in accord
with spacing planes of [130] and [431] of the atomic
http://www.thno.org
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configuration of BSNRs. The selected area electron
diffraction (SAED) patterns of the BSNRs are shown
by simulation indexation (Figure 1D). The lines
correspond to the rod’s interplanar spacing.[29]
High-angle annular dark-field scanning TEM
(HAADF-STEM) illustrate bismuth (Bi) (red) and
sulfur (green) (Figure 1E). The XRD shown in Figure
1F reveals that all peaks are indexed into an
orthorhombic crystal (JCPDS no. 01-089-8963),
indicating high quality of crystallization. The XRD
patterns of the BSNRs match with reported values in
the literature.[30-32] BSNRs present peaks that are
assignable to the orthorhombic structure (JCPDS no.
01-089-8963). BSNRs are elongate along the [130]
direction, representing the crystal plane of the
longitudinal direction (Figure 1C). The energy
dispersive X-ray spectroscopy (EDX) analysis
demonstrated “Bismuth” and “sulfur” signals were
detected in the BSNRs; whereas the copper peaks
originated from the TEM grid (Figure 1F). The percent
metal ions distributed in single particles are 81.68 and
18.32 weight percent of bismuth and sulfur,
respectively, as seen in the inset of Figure 1F (Right
top panel) and these results were similar to X-ray
fluorescence (XRF) analysis results (Supplementary
figure S3). The mean hydrodynamic size of BSNRs by
laser-light scattering is illustrated in Figure 1G. The
size is ~ 205 nm and equivalent to that of NRPV
(Table 1) (Supplementary Figure S1).[33] Phantom
near infrared (NIR) fluorescence images of particles
are shown in Figure 1G. Synthesis and characterization results indicate that 177LuBSNRs could be
employed to design a potential multi-modal
theranostics agent that integrates SPECT and NIR
imaging for a real-time non-invasive visualization of
the virus sanctuary sites, which may provide more
complementary, effective, and accurate information
on progress of HIV-I spread with delivery drugs at
the sanctuary sites. Non-radioactive LuBSNRs and
BSNRs-RPV particles synthesis and characterization
results were similar to that of radioactive particles
(Supplementary SR1 and figure S2, S4-5) and
Table 1.

summarized in Table 2. 177LuBSNRs were incubated
for 3 days at 4ºC or 37ºC in either PBS (pH 7.4) or rat
plasma. Every 24 hours, the percent radioactivity left
in the nanoparticles was calculated. Over the course of
72 hours in PBS at 4ºC or 37ºC, nanoparticles lost
approximately 30% of their radioactivity, with 72%
and 66% remaining, respectively. In 4ºC and 37ºC
plasma,
particles
lost
approximately
50%
radioactivity, with 51% and 56%, remaining,
respectively. 177BSNRs particles lost approximately
30% of their radioactivity when incubated in PBS for
72 hours. This can be attributed to the fact that some
sample is lost (about 10-15%) each time the
nanoparticles are pipetted, as the BSNRs particles
“stick” to the inside of the pipette tip during these
experiments. The greater loss of radioactivity in
plasma can be attributed to the association of BSNRs
with lipids and lipoproteins present in the rat plasma.
We believe this to be the most likely explanation
because we intrinsically doped the BSNRs particles. In
this system the 177Lu ions exist in a tight coordination
with bismuth and sulfur atoms within the core of
nanoparticle which is shielded by an external lipid
layer.[33] These nanoparticles, along with other lipid
coated nanoparticles are known to form associations
with lipids and proteins both in vivo and when
incubated in plasma in vitro. These lipids and
lipoproteins do not pellet when subject to the
centrifugation applied in this experiment and instead
remain floating atop the supernatant. Typically, lipids
and lipoproteins will not pellet unless subjected to
ultracentrifugation.[34] This leads to a higher reading
in the supernatant (due to floating, lipid bound
BSNRs particles) and a lower reading in the pellet,
potentially masking the true stability of the radiolabel
to the particle. Overall, these results demonstrate that
177Lu-labeled particles are stable, with half-lives that
mirror the expected decay of 177Lu intrinsically doped
within nanoparticle cores.

Radiolabeling stability assessment

Size, nm (DLS)
PDI (DLS)
Core size, nm (TEM)
Drug content (%)

In order to accurately localize our nanoparticles
by SPECT imaging, we verified that the radiolabel
remained stably associated within the nanoparticle to
preclude false positive signals in the SPECT scans that
would result if the radiolabel dissociates from the
particle. We developed a process of intrinsically
doping 177Lu atoms into the crystal lattice structure
(formed by regular repeating units of bismuth and
sulfur) of the BSNRs, creating a unique radiolabel
nanoprobe for in vivo studies. The stability results are

Table 1. Physicochemical
BSNRs-RPV particles.
Characteristics

characteristics of

0
24
48
72

PBS
100
88.8 ± 1.0
87.1 ± 4.3
72.6 ± 1.6

and

Formulations
NRPV
BSNR-RPV
341.1
205.3
0.22
0.31
~287.14 (L) X ~158.75 (W)
~70 (L) X ~12 (W)
~83.0
~ 3.50

Table 2. Radiolabeling stability of
PBS at 4ºC and 37ºC.
Time points
(hours)

NRPV

177LuBSNR

in rat plasma and

177LuBSNRs labeling efficiency (%)
4°C
37°C
Plasma
PBS
Plasma
100
100
100
81.8 ± 1.0
86.9 ± 2.8
80.7 ± 1.3
60.3 ± 6.1
72.2 ± 3.2
64.7 ± 5.0
51.2 ± 7.8
66.3 ± 0.6
56.2 ± 0.9

http://www.thno.org
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MDM particle uptake, retention and release
assessments
Time-dependent uptake of the BSNRs-RPV
particles at 12.5 and 25 µg/mL by human
monocyte-derived
macrophages
(MDM)
was
observed over 8 hours (Figure 2A left panels). As
expected, treatment with 25 μg/mL of BSNRs-RPV
provided increased particle uptake compared to the
12.5 μg/mL treatment. Intracellular bismuth and RPV
levels were 11.78 μg/106 cells for bismuth and 3.51
μg/106 cells for RPV with the lower concentration
treatment and 19.32 μg/106 for bismuth and 8.28
μg/106 cells for RPV with the higher concentration
treatment at 8 hours. With particles left in the cell
culture media, the cellular uptake reaches equilibrium
within 8 hours. In retention studies, removal of
particles from the media led to gradual diminution of
intracellular particles (Figure 2A right panels). The
amount of bismuth and RPV remaining in MDM
treated with 25 μg/mL of particles after five days was
51.5% and 54.5%, respectively. Fluorescence
characteristics of BSNRs-RPV and BSNRs particles in
cells were assessed by measuring the relative
fluorescence emission intensity in MDM suspended in
PBS. Fluorescence spectra of BSNRs-RPV in MDM
showed a higher intensity compared to BSNRs.
However, both particles were taken up in MDM, and
fluorescence
intensity
correlated
with
the
concentration of particles (Supplementary Figure
S10D). We hypothesized that with treatment with
BSNRs-RPV particles, uptake and retention of
bismuth in MDM would correlate with the amount of
drug (RPV) taken up and retained by the cells. Figure
2B shows the two-parameter Pearson’s correlation
between bismuth and RPV cell concentration for
uptake (top) and retention (bottom). Comparisons
were performed at each time point and the uptake of
bismuth positively correlated with the uptake of RPV,
with an “r” value of 0.9690. For retention, the
correlation between bismuth and RPV was lower (r =
0.8093), most likely due to the longer period of time
over which the cells were analyzed (details for the in
vitro correlation study are available in the
supplementary results SR3 and Figure S9).
To qualitatively examine the intracellular uptake
of BSNRs-RPV particles and the microstructure of the
cells, we added 25 μg/mL of BSNRs-RPV particles to
MDM for 8 hours, collected the cells and fixed them in
a fixative buffer.[24, 35] Nanoparticle loaded cells
were examined by confocal microscopy (Figure 2C),
TEM (Figure 2D), and validated by NIR fluorescence
using NIR microscopy (Figure 2E). TEM images show
BSNR particles endocytosed by MDM with higher
magnification showing large numbers of BSNRs-RPV
particles in vesicles, observed as black clusters
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distributed within lysosomes and other microvesicles
(Figure 2D). These results were confirmed by
May-Grünwald Giemsa staining that showed particles
in the cells clearly visible by light microscopy
(Supplementary Figure S10A-C). We assessed the
surface topography of treated cells by AFM to
determine characteristic morphological changes
compared to control cells. BSNRs treated
macrophages displayed a surface pseudopodium like
morphology compared to control cells. AFM results
demonstrated that particles were taken up in the cells
with a slight change in cell surface morphology
(Figure 2F).
Antiretroviral activity was assessed in MDM to
determine the activity of BSNRs-RPV and NRPV
particles. Cells were pre-treated with 12 or 25 μg/mL
of NRPV and BSNRs-RPV for 8 hours before being
challenged with HIV-1ADA, a macrophage tropic
strain, at days 1, 3, 5 and 8 after treatment. Ten days
after infection, culture supernatants were collected
and HIV-1 reverse transcriptase (RT) activity was
assessed as a measure of viral replication
(Supplementary Figure S11). The remaining cells
were fixed and HIV-1 p24 staining was used as a
qualitative measurement of viral infection (Figure 3).
Treatment with 12.5 or 25 μg/mL of BSNRs-RPV
showed a notable reduction in HIV-induced
multinucleation of macrophages at days 1, 3, 5, and 8
compared to positive control (HIV infected
macrophages). These results paralleled RT activity
measurements while demonstrating comparable
antiretroviral responses for NRPV. The antiretroviral
activity of BSNRs-RPV (98% HIV-1 inhibition) was
similar to that of NRPV (98% viral inhibition) after 8
days of infection without any apparent difference of
the BSNRs-RPV concentrations.

Biodistribution and cellular localization of
particles by SPECT, LA-ICP-MS and TEM
imaging
Our laboratory has been developing a
theranostic, nanoparticle-based imaging platform that
can be used to predict the long-term biodistribution of
these medications by use of MRI and SPECT imaging
early in the treatment regimen.[24, 33, 35] We
hypothesized that a rod-shaped nanoparticle (termed
“nanorods”) approximately the same size as our
long-acting RPV nanocrystals, created from safe,
(bismuth and sulfur) non-toxic “green elements”[36]
could serve as an accurate predictor of RPV long-term
biodistribution by intrinsically doping the BNSRs
with 177Lu, a gamma-emitting radioisotope. If
successful, a theranostic imaging platform would
allow the creation of a data library to predict drug
biodistribution in patients with greater precision than
http://www.thno.org
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traditional PK and biodistribution analysis without
the need for invasive and experiment ending isolation
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of tissue samples.

Figure 1. Synthesis and characterization of multimodal particles. Uniform rod shaped BSNRs were made by a modified solvothermal method in the presence of
oleylamine and oleic acid.[26, 28, 29] Oleylamine was the solvent for thioacetamide in forming the BSNRs (Supplementary Figure S1). Low-resolution TEM images of BSNRs
are illustrated in (A). The BSNRs dimensions were approximately 12 nm in diameter by 70 nm in length. High-resolution TEM images of twin BSNR particles with lattice planes
are shown in (B) with corresponding electron diffraction patterns. These are illustrated through the drawing of [4 3 1] and [1 3 0] space groups in the vector directions (C). The
selected area electron diffraction (SAED) pattern of BSNRs are shown by simulation indexation. The indexation-detected lines correspond to characteristic interplanar spacing
of the BSNR’s single crystal structure in (D). The bismuth (red) and sulfur (green) element mapping showed element localization within the particles by corresponding high-angle
annular dark-field electron microscopy in (E). XRD patterns, correlations with HR- TEM, SAED and simulated data sets confirmed the particle’s structural configurations (F left
panel). Quantitative measurements of particle element distribution were made by energy dispersive X-ray spectroscopy (F right panel). The hydrophobic and hydrophilic
properties of the lipid coated particles are shown in the inset. The vial BSNRs were dispersed in cyclohexane. The vials contain mixtures of cyclohexane. The third vial shown
illustrates the BSNRs particle hydrophilic properties produced by lipid coatings. These were dispersed in water. The schematic diagram of the particle’s configuration is shown
on the vial top. The hydrodynamic size distribution of lipid-coated drug loaded particles as determined by DLS was compared against NRPV (G left panel). Excitation and emission
spectra of BSNRs (g middle panel) are illustrated. BSNRs NIR fluorescence imaging is shown (G right panel). Chemical composition of BSNRs was assessed by X-ray fluorescence
and demonstrated the following; Bismuth = 88.61 mass% and sulfur = 11.38 mass% contents (Supplementary figure S3)

http://www.thno.org
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Figure 2. Human macrophage particle uptake and retention. Human monocyte-derived macrophage uptake and retention of lipid-coated RPV loaded BSNRs were
determined at two treatment concentrations (12.5 and 25 µg/mL as bismuth content) (A). Bismuth and RPV content were determined by ICP-MS and UPLC-MS/MS analysis,
respectively. Pearson’s correlations of average bismuth and RPV content over time for both uptake and retention were determined (B). These served as a cross-validation of the
drug loaded particle integrity in cells over the time periods used for analysis, presented in supplementary figure S9). To qualitatively determine cell uptake, macrophages were
treated with 25 µg/mL of the BSNRs particles (25 µg/mL) for 8 hours and confocal (C), TEM (D) and NIR (E) cell images were obtained. The surface morphology of particle-loaded
cells was assessed by AFM (F). Statistical differences were determined using two-way ANOVA between groups with a Bonferroni’s post hoc-test to correct for multiple
comparisons. ***p < 0.001; ****p < 0.0001.

We assessed the effectiveness of 177LuBSNRs
particles as multimodal contrast agents for
non-invasive real time imaging of biodistribution to
the lymphoid organs in Balb/c mice. Biodistribution

of 177LuBSNRs was investigated by SEPCT/CT at 6,
12, 24, 48, and 120 hours after IV injection, as shown in
Figure 4. Three-dimensional image reconstruction
and autoradiographic counts were performed in
http://www.thno.org
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excised livers and spleens at days 2 and 5 (48 and 120
hours, respectively). Quantitative studies were
performed by measuring radioactivity by gamma
scintillation
spectrometry
and
by
SPECT
three-dimensional images to draw regions of interest
(ROIs) and obtain counts per unit volume of tissue.
The three-dimensional rendered SEPCT/CT images
of the thoracic duct (cisterna chyli), liver, spleen, gut
and lymph nodes are illustrated in Figure 4A and B
(coronal and sagittal views, respectively), and
illustrate the transition of 177LuBSNRs from the liver
to lymph nodes over the 120 hour period. In the early
time points high deposition of 177LuBSNRs in liver
and spleen was observed. Radioactive signals in liver
decreased steadily over time, with less than half of the
radioactivity remaining by 120 hours. A strong signal
was observed in spleen within 6 hours which
increased over time. After 12 hours, 177LuBSNRs were
readily observed in the gut and lymph nodes, in
addition to liver and spleen. (Figure 4A-B and
supplementary video files SV1-SV5;6 to 120 hours
time points). At 24 hours post injection, 177LuBSNRs
were deposited largely in spleen and were diminished
in the liver. Importantly, 120 hours after particle
administration, the particles were highly retained in
the spleen while minimal levels were found in the
liver (autoradiography results Figure 4C). Particle
levels in the lymph nodes remained constant from 12
to 120 hours. Ex vivo gamma scintillation examination
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was used to quantify radioactivity in liver, spleen and
lymph nodes. Values of radioactivity in spleen were
258 ± 9 and 337 ± 21 %ID/g at 48 and 120 hours,
respectively. In contrast, liver radioactivity was 84 ± 8
and 63 ± 8 %ID/g at 48 and 120 hours, respectively
(Figure 4D). Radioactivity in axillary and inguinal
lymph nodes remained constant between the two time
points (Figure 4D left panel). This data was
confirmed by 3D ROIs from SPECT images (Figure
4D right panel). Even after 120 hours, no SPECT
signal was found in the bladder, demonstrating the
stability of 177LuBSNRs in vivo. The distribution of the
177LuBSNRs in the liver and spleen at 48 and 120 hours
was heterogeneous as illustrated by ex vivo
autoradiography (Figure 4C). In the spleen, high
particle numbers accumulated in the red pulp with
limited accumulation in the white pulp.
The utility of BSNRs particles as in vivo X‐ray CT
contrast agents was also demonstrated using the
newer technique of small animal radiation research
platform (SARRP) (Xstrahl, Inc.) as illustrated and
cited in supplementary Figure S14.[37]
Cellular distribution of the particles in the spleen
was investigated by laser ablation inductively
coupled plasma mass spectrometry (LA-ICP-MS)
imaging. Schematic representation of preparation of
in vitro phantoms using chicken breast homogenates
mixed with particles and creation of the calibration
curve from matched matrix is shown in Figure 5A.

Figure 3. Antiretroviral activities. Antiretroviral activity was determined in macrophages treated for 8 hours with NRPV and BSNRs-RPV particles (12.5 and 25 µg/mL), and
then infected with HIV-1ADA at a multiplicity of infection (MOI) of 0.1 infectious particles per cell at days 1, 3, 5, or 8 after drug loading. At 10 days after infection, progeny HIV virion
production was determined by P24 staining of cells. Antiretroviral activity was comparable for BSNRs-RPV and NRPV. Results for associated HIV RT activity in cell culture medium
are available in supplementary figure S11.

http://www.thno.org
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The BSNR particles demonstrated very high spatial
resolution, sensitivity and low limits of detection
(LOD) close to 0.001 ppm in chicken breast tissue
homogenates (Figure 5B and supplementary Figure
S15-16). Spleen tissues prepared using this approach
met the requirements of LA-ICP-MS analysis.[38] The
BSNRs particles ex-vivo cellular distribution in spleen
using LA-ICP-MS imaging of the bismuth signal
showed a heterogeneous distribution pattern of the
particles (Figure 5C, D). The results indicated that
BSNRs and BSNRs-RPV particles deposited in the
spleen to a higher extent on day 5 compared to day 2.
Furthermore, distribution of particle patterns in the
marginal zones of the spleen was much higher
compared to distribution in white and red pulp.
Quantitative analysis of the images demonstrated that
the primary site of accumulation for particles is in the
marginal zones where the maximum number of
macrophages are located (Figure 5D, lower left
panel). Particles also distributed to the red and white
pulp, but to a lesser degree. BSNRs and BSNRs-RPV
were uniformly distributed in matrix-matched spleen
samples without aggregation (Figure 5D, lower right
panel). We hypothesized that the particles would be
taken up and sequestered by macrophages in tissues
leading to particle depot formation that would allow
slow release of therapeutic amounts of particles over
time. To test our hypothesis, we injected mice
intravenously with BSNRs (G6) and prepared liver
and spleen sections for TEM imaging at days 2 and 5
(Figure 6). Macrophages containing BSNRs could
readily be found with a black aggregate in liver and
spleen at days 2 and 5 (Figure 6, Row I). At higher
magnifications, macrophages show large amounts of
intracellular BSNRs particles (Figure 6, Row II).
Increasing magnifications to 5x that of row II
allowed validation of particle deposition in
macrophages with clear visualization of individual
BSNRs, and clusters of BSNRs within cells (Figure 6,
Row III). The fact that BSNRs in cells appear to
cluster, suggests the particles are taken up by
endosomal vesicles in a similar manner to that
observed with other nanoparticle platforms.[24, 35]

Tissue drug and metal analysis profile
To determine whether

177LuBSNRs

could provide an accurate estimate of the long-term
biodistribution
of
long-acting
antiretroviral
medications, we compared the distribution of BSNR
particles to that of NRPV as a model long-acting
medication. As shown in Figure 7A, male Balb/c mice
received a single intravenous injection of either
therapeutic particles (NRPV) or imaging particles
(BSNRs) at various doses and in combination. The
biodistribution of the different particles was assessed
at various times post-injection using in vivo SPECT
imaging and ex vivo ICP-MS and UPLC-MS/MS
analyses for metal and drug content in tissues and
plasma. Additionally, in vivo SPECT and LA-ICP-MS
imaging results were complemented by measuring
radioactivity in excised tissue samples of treated mice
by gamma scintillation analysis and autoradiography.
The various treatment groups are shown in Figure 7B.
Table 3 displays the analytical technique used to
measure each parameter for every group and at what
time point each parameter was measured. In brief, the
UPLC-MS/MS results for RPV content in tissues for
groups treated with NRPV or BSNRs-RPV are shown
in Figure 7C.
The levels of RPV in liver were similar for
animals treated with a high dose (45 mg/kg) of NRPV
alone (G1) or in combination with BSNRs (G3). After
two days, the RPV content in livers from G1 animals
was approximately 6883.2 ± 4074.54 ng/g. By day 5
the liver RPV concentration decreased to 317.2 ± 61.15
ng/g. By the end of the study, 28 days after injection,
21.3 ± 5.7 ng/g RPV remained in the livers of G1
animals. RPV content in the livers of G3 (BSNR plus
NRPV) animals showed a similar pattern with RPV
content of 10,033.6 ± 1344.96 ng/g, 291.7 ± 93.28 ng/g,
and 25.0 ±1.7 ng/g for days 2, 5, and 28, respectively.
The pattern of RPV concentration over time in the
livers of animals treated with a lower dose (5 mg/kg)
of NRPV (G2) or BSNRs-RPV (G4) was also similar.
G2 livers contained 139.9 ± 37.9, 26.8 ± 2.6, and 2.1 ±
0.55 ng/g RPV on days 2, 5, and 28, respectively. RPV
content in G4 livers was lower than that of G2 livers at
19.7 ± 15.6, 1.6 ± 0.35, and 1.3 ± 0.67 ng/g RPV on days
2, 5, and 28, respectively, but the trend over time was
similar.

particles

Table 3. Real time iv vivo drug biodistribution measurement by design of multimodal theranostic and therapeutic nanoparticle study.
Groups

Formulations
Dose mg/kg

G1
G2
G3
G4
G5

NRPV-High
NRPV-Low
BSNRs + NRPV
BSNRs-PRV
177LuBSNRs

G6

BSNRs

RPV
45
5
45
5
~1000
µCi
--

SEPCT/CT

In vivo test
Gamma Counter

UPLC-MS/MS

ICP-MS

Bi
--80
80
~80

Time (hour)
----6,12,24,48, 120

Time (day)
----2, 5

Time (day)
1,2,3,5,7,14,21,28
1,2,3,5,7,14,21,28
2,5,28
2,5,28
--

Time (day)

80

--

--

--

2,5,28

2,5,28
2,5,28
--
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Figure 4. Real time biodistribution of multimodal particles in mouse tissues. SPECT imaging was used to assess distribution of intrinsically labeled 177LuBSNRs.
177LuBSNRs particles (177Lu = ~1000 μCi, particle size of ~ 200 nm based on DLS) were injected intravenously into Balb/c mice. Whole body coronal SPECT/CT images were
collected at 6, 12, 24, 48 and 120 hours after injection (A). Corresponding sagittal images are also shown (B). 177Lu radioactivity intensity is reflected by the colors shown. High
signal intensity was detected in the lymph nodes (LN), liver, spleen and gastrointestinal (GI) tract tissues. Images were adjusted for an appropriate fitting with the tracer
distribution. The ex-vivo autoradiography studies (C) show homogeneous accumulation of 177LuBSNRs in the liver tissue that decreases over time (48 hours > 120 hours).
Breakdown of particles in liver could lead to free 177Lu absorption in bone, as seen near the lower spinal cord at later times. Accumulation of 177LuBSNRs in spleen showed a
heterogeneous distribution pattern and increased particle concentrations over time (120 hours > 48 hours). Quantitative studies were done by measuring radioactivity by gamma
scintillation spectrometry analysis (left) and SPECT 3D images were used to drawn ROIs (right) to obtain radioactivity counts per volume of tissue (D). Significant differences
were determined using two-way ANOVA between groups followed by a Bonferroni’s post-hoc test to correct for multiple comparisons. *p < 0.05, ***p < 0.001; ****p < 0.0001.
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Figure 5. Tissue particle localization by LA-ICP-MS. Schematic representation of preparation of in vitro phantoms using chicken breast homogenates mixed with BSNRs
particles and creation of the calibration curve from matched matrix (A). Determination of spatial resolution, sensitivity and lower limit of detection (LOD) of BSNRs particles in
breast homogenates tissues (B). Lower limit of bismuth detection analyzed by LA-ICP-MS by preparation of “phantom tissue” with particle mixture by using chicken breast tissues
homogenate. Serial dilutions of particles plus tissues homogenate mixture were used to create a calibration curves from LA-ICP-MS imaging spots. Bismuth was detectable in
tissue mimics at all calibration points. Fifty micrometer resolution is needed to properly observe subcellular distribution. Distribution of particles in spleen slices was determined
on days 2 and 5 after injection of BSNRs and BSNRs-RPV particles in mice (C). The distribution of the particles in the spleen was monitored with high spatial resolution and
sensitivity using LA-ICP-MS imaging. Bismuth signal in spleen sub regions after injection of particles (D) showed a heterogeneous distribution pattern. Higher distribution in the
macrophage-rich marginal zone compared to white pulp and red pulp was observed (D). The uneven particle distribution pattern observed across the structural architecture of
the spleen and confirmed by quantitative measurements by LA-ICP-MS can be explained by higher macrophage populations in marginal zone that are specialized for uptake and
storage of particles. A two-way ANOVA between groups followed by a Bonferroni’s post-hoc test to correct for multiple comparisons was performed to determine statistical
differences. ****p < 0.0001; n.s.= not significant. (Associated controls and additional experimental results analysis are presented in supplementary Figure S15-16)

RPV concentrations in the spleens of G1 (NRPV
45 mg/kg) animals were lower than those in liver on
day 2 but higher on days 5 and 28 (Figure 7C).
Concentrations were 5250.4 ± 3063 ng/g RPV on day
2, 683.6 ± 221 ng/g RPV on day 5 and 42.5 ± 16.86
ng/g RPV on day 28. For G3 (BSNR plus NRPV

45mg/kg) animals, RPV concentrations in spleen
were twice that of the liver RPV concentrations on all
days with values of 22,020.1 ± 3971 ng/g RPV on day
2, 569.2 ± 215.4 ng/g on day 5, and 67.7 ± 11.04 ng/g
on day 28. RPV content in the spleens of G2 and G4
animals, which received a lower dose of NRPV or
http://www.thno.org

Theranostics 2020, Vol. 10, Issue 2
BSNRs-RPV, were similar to concentrations in
autologous livers. For G2 spleens, RPV concentration
was 189.2±64.5 ng/g on day 2, 24.4±3.8 ng/g on day 5,
and 3.8±2.5 ng/g by day 28. Splenic RPV
concentrations for G4 animals closely matched that
observed for G2 animals with values of 138.8±121
ng/g, 2.6±3.6 ng/g, and 6.71± 3.3 ng/g RPV on days 2,
5, and 28, respectively.
Concentration of RPV in the lymph nodes was
less than that of liver and spleen, but followed a
similar pattern over time as in those tissues (Figure
7C). For G1 animals, RPV concentrations in the lymph
nodes were 156.6 ± 31.6 ng/g RPV on day 2, 171.4 ±
71.8 ng/g on day 5, and 50.9 ± 16.8 ng/g on day 28.
Similar values were obtained from lymph nodes
excised from G3 animals with RPV concentrations of
160.9 ± 52.5 ng/g, 37.3 ± 12.4 ng/g, and 80.4 ± 37 ng/g
on days 2, 5, and 28, respectively. RPV concentrations
in lymph nodes of animals treated with the low dose
of NRPV (G2) decreased over time with values of 22.8
± 7.3 ng/g on day 2, 4.1 ± 3.8 ng/g on day 5, and 5.4 ±
1.2 ng/g on day 28. However, the RPV content of
lymph nodes from animals treated with RPV loaded
BSNRs (BSNRs-RPV) was lower than that in G2
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animals on day 2 (7.1 ± 4.4 ng/g) and remained
constant thereafter through day 28 (5.4 ± 1.8 ng/g).
Bismuth concentrations in tissues over time from
animals in G3 (BSNRs plus NRPV), G4 (BSNRs-RPV)
and G6 (BSNRs only) were determined by ICP-MS
analysis. The results for liver, spleen, lymph nodes,
and kidneys are shown in Figure 7D and E. For G6
animals, bismuth concentration in the liver increased
significantly (P<0.05) from day 2 to day 5, from 183.3
± 26.19 g/g to 237.2 ± 19.41 g/g and decreased
slightly to 200.7 ± 17.88 g/g by day 28. Bismuth
content in the livers of G3 animals showed a similar
pattern with a significant increase in bismuth
concentration from day 2 to day 5 (200.0 ± 26g/g
bismuth to 246.7 ± 18.3 g/g bismuth) followed by a
non-significant drop to 223.9 ± 19.3 g/g on day 28.
Again, a similar pattern was observed in G4 livers in
terms of bismuth concentration. On day 2, liver
concentration was 181.9 ± 36.4 g/g bismuth followed
by a significant accumulation by day 5 (251.6 ± 42
g/g) and a non-significant decrease by day 28 (241.1
± 13.7 g/g).

Figure 6. Subcellular particle localization. TEM images were obtained for liver and spleen 2 and 5 days after injection of BSNRs particles (80 mg /kg bismuth). Panels (ii) and
(iii) are higher-powered images from black color particles deposited regions by from panel (i). Presence of BSNRs particles (black dots) can be visualized in macrophages in both
liver and spleen sections
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The concentration of bismuth in spleens showed
a pattern of non-significant accumulation between
days 2 and 5, followed by a significant increase in
concentration between days 5 and 28 for each of the
three groups of animals that received BSNRs (G3, G4,
and G6). The concentration of bismuth in G3 spleens
increased from 72.4 ± 7.0 g/g to 117.4 ± 11.2 g/g
from day 2 to day 5 and then further increased to
137.8 ± 7.6g/g by day 28. For G4 spleens a similar
pattern was observed, with a non-significant increase
from 109.7 ± 4.9 g/g to 134.4 ± 4.8 g/g bismuth
from day 2 to day 5 followed by a larger, significant
increase to 170.6 ± 13.1 g/g by day 28. Bismuth
concentration in G6 spleens followed the same pattern
with measured values of 97.5 ± 10.3 g/g, 109.5 ± 13.7
g/g, and 162 ± 13.1 g/g bismuth on days 2, 5, and
28, respectively.
Concentrations of bismuth in lymph nodes of
G3, G4, and G6 animals were lower than that in the
spleen
and
liver.
However,
lymph
node
concentrations of bismuth did not change
significantly over the course of 28 days for any of the
three groups. For G3, bismuth concentration in the
lymph nodes on day 2 was 1.84 ± 0.001 g/g with
concentrations on day 5 and day 28 of 0.89 ± 0.2 g/g
and 0.35 ± 0.5 g/g, respectively. The bismuth
concentration in the lymph nodes of G4 animals was
similar to that in G3 animals with values of 0.88 ± 1.3
g/g, 0.34 ± 0.07 g/g, and 0.64 ± 0.7 g/g on days 2,
5, and 28, respectively. G6 animals received only
BSNRs and the bismuth concentration in lymph nodes
was 0.31 ± 0.3 g/g on day 2, 0.89 ± 0.7 g/g on day 5,
and 0.36 ± 0.1 g/g, on day 28. Overall the
concentration of bismuth in the lymph nodes of all
animals remained relatively constant over the 4 weeks
post-treatment. Bismuth concentration was also
measured in the kidneys of G3, G4, and G6 animals by
ICP-MS (Figure 7E, left panel). Again, all groups
followed a similar pattern of Bismuth concentration
over time. Between days 2 and 5, the concentration of
bismuth changed non-significantly from 3.34 ± 0.35
g/g to 3.65 ± 0.21 g/g, 4.35 ± 0.3 g/g to 2.82 ± 0.15
g/g, and 6.17 ± 0.2 g/g to 9.24 ± 0.05 g/g for G3,
G4, and G6 animals respectively. From day 5 to day 28
all groups saw a significant accumulation of bismuth
in the kidneys with concentrations of 9.60 ± 1.2 g/g,
8.09 ± 1.07 g/g, and 9.24 ± 0.70 g/g for G3, G4, and
G6, respectively.
RPV concentrations were assessed over time for
groups that received NRPV (G1, G2, G3) or
BSNRs-RPV (G4) (Figure 7E, center and right panels).
On day 1 RPV concentration in G1 plasma was 520.0
ng/mL and declined rapidly to 76.7 ng/mL by day 7,
then remained fairly constant until day 28 at 61.9
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ng/mL (Figure 7E, center panel). Plasma
concentration of RPV in G3 animals followed a similar
pattern over time. On day 1, RPV concentration in G3
plasma was 1229.1 ng/mL and then decreased to 5.25
ng/ml at day 7. From day 7 to day 28 there was a very
slow decrease in plasma concentration to 1.4 ng/mL.
For G2 animals, RPV concentration was 137.6
ng/mL at day 1 and declined to 17.8 ng/mL by day 5
(Figure 7E, right panel). From day 5 until day 28,
plasma RPV concentration slowly declined to 10.8
ng/mL. For G4 animals treated with BSNRs-RPV,
plasma RPV concentration on day 1 was relatively
low, 3.1 ng/mL, but increased to 18.4 ng/mL by day
14. From day 14 to day 28 the plasma RPV
concentration remained constant and on day 28
plasma RPV was 10.2 ng/mL. These results suggest a
slower release of RPV into the plasma from
BSNRs-RPV than from NRPV alone, potentially
prolonging its effects in the body. In vivo treatment
with BSNRs, BSNRs-RPV, NRPV, and combinations
of BSNRs plus NRPV produced no observed toxicity
in liver, kidney, or pancreas as determined by serum
chemistry
and
histological
analysis
results
(Supplementary figures 20 and 21).

Metadata analysis
LA ARVs could overcome limitations in
HIV/AIDS therapeutic regimens that limit optimal
clinical outcomes.[14] The ability to sustain plasma
and tissue drug levels beyond the plasma 90%
inhibitory concentration (IC90) for months would
reduce pill burdens, increase regimen adherence and
reduce adverse events that plague current
medications. This would also lift the psychological
stigma for strict daily regimens reminding patients of
disease and impacting mental health.[16, 39, 40] To
simplify measurements of LA ARV efficacy by
pharmacokinetic (PK) and biodistribution (BD) tests
and optimize dosing, theranostics was introduced.[16]
The traditional PK and biodistribution assessments
which require end-point animal sacrifice and organ
removal could be exchanged by bioimaging-based
measurements.[24] To determine whether rod-shaped
particles were reflective of the PK and biodistribution
of LA NRPV, biodegradable BSNRs formulations
were created. These newly synthesized particles were
then deployed as a predictor of RPV long-term
biodistribution. 177LuBSNRs were used as a
theranostic imaging platform to compare six
treatment regimens. After group data was acquired
across time, predictive values were determined for
particle drug biodistribution. Pearson’s correlation
coefficients were calculated for group comparisons of
RPV concentrations, bismuth concentrations, SPECT
ROI (Supplementary figure S13), and gamma
http://www.thno.org
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scintillation counts from excised organs. Means of
absolute “r” values with p ≤ 0.05 were used to create
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the “multiple ribbon bar graph” (Figure 8).

Figure 7. BD and PK. A schematic representation of the nanoformulated therapeutic particles (NRPV) and multimodal imaging particles (BSNRs) is shown in (A). The type of
treatment and particle size administered to mice, and analyses techniques used are illustrated. Treatment scheme for intravenous injection of high dose NRPV (G1) (45 mg/kg
RPV), low dose NRPV (G2) (5 mg/kg RPV), BSNRs (80 mg/kg based on bismuth) plus NRPV (45 mg/kg RPV) (G3), BSNRs-RPV (80 mg/kg based on bismuth plus ~5 mg/kg RPV)
(G4), 177LuBSNRs (37 MBq = ~1000 µCi = ~ 80 mg/kg based on bismuth) (G5) and plain BSNRs (80 mg/kg based on bismuth) in male Balb/cJ mice is shown in (B). RPV levels in
liver, spleen, and lymph nodes 2, 5, and 28 days after treatment of mice with NRPV high and low dose, BSNRs plus NRPV and BSNRs- RPV were determined by UPLC-MS/MS
(C). Bismuth contents in liver, spleen, lymph nodes and kidneys from mice treated with BSNRs and BSNRs plus NRPV and BSNRs-RPV were determined by ICP-MS from days
2, 5, and 28 (D-E left side). Plasma RPV concentrations of mice treated with NRPV high and low dose, BSNRs plus NRPV and BSNRs- RPV were determined on days 1 through
28 by UPLC-MS/MS. Statistical differences were determined using two-way ANOVA between groups. Multiple comparison correction was done using a Bonferroni’s post-hoc
analysis. *p < 0.05 (p = 0.0256); ***p < 0.001; ****p < 0.0001; n.s.= not significant.
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From imaging analyses, biodistribution and PK
studies data for various parameters were measured in
plasma and tissues for 6 treatment groups with the
analysis parameter depending on the treatment
(supplementary figure S12) as shown in Table 3.
These parameters included RPV concentration
(UPLC-MS/MS), bismuth concentration (ICP-MS),
SPECT signal, and gamma counts for excised organs.
To assess the predictive value of the BSNRs to
estimate long-term biodistribution of LA ARVs such
as NRPV, we used Pearson’s correlation analysis for 2
parameter comparison on averaged data collected
from different groups on the same day. Correlation
“r” values were generated for each comparison and
statistically significant correlations with r > 0.5 were
plotted. For same day comparisons in the liver, the
highest degree of correlation was between RPV and
bismuth on day 2 (r = 0.9796). Additionally, G1 RPV
concentration in the liver correlated significantly with
bismuth concentration in G4 animals treated with
BSNRs-RPV (r = 0.9412). Interestingly, the lower dose
of NRPV (G2) correlated extremely well with our
BSNRs-RPV (G4) in terms of RPV concentration even
to 28 day with r = 0.8536. These data demonstrated
that RPV loaded BSNRs reflected the biodistribution
of NRPV. Gamma scintillation analysis of G5 livers
excised 5 days post-treatment correlated with bismuth
concentration (r = 0.9005). Furthermore, gamma
counts of excised day 5 livers correlated with RPV
concentration on the same day (r = 0.8264). Most
importantly, we observed that SPECT signal and RPV
concentration on day 5 were strongly correlated (r =
0.8676). In spleen, RPV concentration (G2) correlated
with bismuth concentration, gamma scintillation
counts, and SPECT signal (r = 0.9412, 0.8361, and
0.5593, respectively). SPECT signal (G5) in spleen also
significantly correlated with bismuth concentration
on day 2 (r = 0.8993) for animals treated with
BSNRs-RPV (G4). In lymph nodes, SPECT signal (G5)
correlated with RPV concentration on day 2 from
multiple groups including G1, G2, and G3 with r =
0.5259,
0.5416,
and
0.6936,
respectively
(Supplementary figure 19 graphs A, C and E). We
observed an even stronger correlation between SPECT
signal (G5) and RPV concentration (G2) on day 5 (r =
0.9278) (Supplementary figure 19 graph D). Day 5
lymph node SPECT signal also correlated with
bismuth concentration (r = 0.7283), providing
evidence that the SPECT signal could be used to
predict RPV concentration in vivo. Gamma
scintillation counting was also closely associated with
bismuth and SPECT signal (r = 0.8545 and 0.9731
respectively).
The data, in toto, demonstrates that SPECT signal
reflects RPV drug concentrations. We also looked at
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the associations between various different data
combinations (e.g., RPV vs Bismuth) acquired at
different times to determine the predictive value of
the BSNRs platform. In the lymph nodes, we observed
that SPECT signal at 2 days post-treatment was
predictive for RPV concentration on day 28, for both
high dose NRPV group (G1) and RPV-BSNRs (G4)
with strong correlation values (r = 0.7709 and 0.7830,
respectively). SPECT signal from day 2 was also
predictive for day 28 bismuth concentration in the
lymph node (r = 0.7643). In the spleen, SPECT signal
from days 2 and 5 could be predict bismuth
concentration on day 28 (r = 0.9255 and 0.9044,
respectively), while day 2 bismuth concentrations
correlated with day 28 RPV concentration (r = 0.987).
In liver, gamma scintillation counts from day 5
provided the best correlative values in terms of RPV
and bismuth content on day 28. Day 5 gamma
scintillation
counts
correlated
with
RPV
concentrations from G1, G2, and G3 (r = 0.8591,
0.9142, and 0.6801, respectively). Group correlations
for spleen parameters were also determined and are
illustrated in supplementary figures S17-19. Overall
the correlative data obtained from the tissues
provides evidence that bioimaging by SPECT
accurately predicts LA RPV drug levels in lymphoid
tissues.

Discussion
While drug-encased theranostic nanoparticles
are developed for cancer and inflammatory disease
[41-44] little has yet to be achieved for HIV
diagnostics and treatments. Thus, an immediate need
warrants the creation of theranostic ARV particles
optimized for size, shape, and structure to ensure
proper distribution to CD4+T cells and macrophages.
All will ensure improved PK as the drug’s apparent
half-life is extended. To achieve these goals and to
simplify assessments of LA ART for PK,
biodistribution and dosing theranostics was
employed. Traditional PK requires end-point animal
sacrifice and organ removal. These we posit can be
exchanged by bioimaging tests. To determine whether
rod-shaped particles are reflective of LA RPV size and
shape and as such could predict drug biodistribution
biodegradable bismuth and sulfur formulations were
created. We assessed, in real time, the biodistribution
of drug loaded multimodal radiolabeled particles
(177LuBSNRs) and used them to predict LA RPV
pharmacological properties. The BSNRs-RPV particles
were used successfully to determine ARV
effectiveness through measures of drug distribution
into HIV tissue and cell reservoirs by noninvasive
measurements.
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Figure 8. Multiplex statistical data analyses. Pearson’s correlation coefficients metadata were generated from SPECT, UPLC-MS/MS (RPV), ICP-MS (Bismuth) and gamma
scintillation analysis of liver (A), spleen (B), lymph node tissues (C). Key components calculated across groups with fitting Pearson’s correlation coefficients using a p-value ≤ 0.05
are shown as multiplane ribbon plots (Supplementary Figure S17-19).
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Over the past two decades our laboratories
investigated the role of particle size and shape for
their distribution.[24, 35, 45-47] The results showed
that rod-shaped nanoparticles were efficient and
rapidly taken up in macrophages.[33, 48-50] The
combinatorial effect of particle size and shape reflects
Fc receptor mediated macrophage engulfment and
internalization. Indeed, nanoformulations with a rod
shape were known to be taken up by macrophages at
faster rates than spherical particles.[48] Indeed, prior
research into the shape of mesoporous silica
nanoparticles demonstrated that those particles with
larger aspect ratios were internalized faster.[51] These
results supported other previously published
reports.[52, 53] Based on need coupled with prior
studies demonstrating a “rod-like” particle shape is
an efficient entry into macrophages as the principal
depot, we developed theranostic ARV formulations to
reflect the shapes of native LA drugs.[54-57]
Moreover, coating the surface of nanoparticles with
polyethylene glycol (PEG), termed “PEGylation”, was
shown to improve the efficiency of drug and gene
delivery.[58, 59] Firstly, PEGylation reduces
aggregation of particles by diminishing the
association with nontargeted serum and tissue
proteins and resulting `stealth' behavior.[60] The PEG
polymers reduces charge-based contact typical of
proteins and small-molecule interactions.[61] Second,
PEGylation increases the circulation time of
nanoparticles by preventing non-specific uptake by
the liver and spleen.[62] Third, PEGylated
nanoparticles have increased solubility in buffer and
serum due to the hydrophilic ethylene glycol repeats.
Fourth, PEGylation reduces systemic and cellular
toxicities of nanoparticles.[63] In all, these properties
underlie the properties of the PEG polymer formed by
repeating ethylene glycol monomers. PEG polymers
of varying lengths exist and some reports number of
ethylene glycol monomers in a chain of up to 40. PEG
molecular weights are up to 20,000 Da and the
thickness of any grafted PEG correlates with its
molecular weight and density as present on the
nanoparticle surface.[64] In our studies, using
PEG2000 was enough to consistently generate
nanorods of the same size as our nanoformulated
RPV. PEGylation also results in a tighter size
distribution of produced particles by decreasing
aggregation. In terms of increasing therapeutic
efficacy, PEG coatings increase the circulation half-life
of nanoparticles but also improve the penetration of
particles into “biological barriers”, including reducing
interactions with tissue extracellular matrix, cellular
barriers, and biological fluids such as mucus,
especially when delivering poorly water-soluble
drugs.[65, 66] Overall, it is a combination of the
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density of PEG polymers and the number of
polyethylene glycol repeats/polymer that affect
therapeutic efficacy and particle size.
LA ART is a means to overcome limitations in
HIV therapeutic regimens that often preclude best
clinical outcomes.[14-16, 67] The ability to sustain
plasma and tissue drug levels above effective plasma
concentrations for months would have a real impact
on the care and prevention of viral infection.
Moreover, it would reduce pill burden, increase
regimen adherence, and limit adverse events that
plague current drug regimens. This would also lift the
stigma for strict daily regimens that remind patients
of their disease.[16, 39, 40]
As a result, we hypothesized that BSNRs with a
clear-cut, rod shape morphology that matches the
shape and size of our long acting nanoformulated
therapeutic drug nanoparticles provide a platform to
accurately and efficiently predict long-term
therapeutic drug biodistribution and that these tests
could be performed by SPECT and LA-ICP-MS. To
achieve this goal, theranostic particles were made of
identical size and morphology (“rod-shaped”) as LA
ARVs that are used currently in phase III treatment
paradigms.[68] This was achieved in step-wise
fashion. First, we created lipid coated 177LuBSNRs as a
multimodal imaging particle for non-invasive and
real-time imaging. Second, LA RPV (NRPV) was
deployed to model drug biodistribution. Imaging
enabled particle tracking in real time and specifically
tracked the distribution into “putative” tissue
reservoirs of infectious virus. Third, the particles
allowed direct and real-time visualization for the
abilities of drug to distribute to lymphoid organs.
Fourth, state of the art characterizations that included
surface modification of imaging particles with a thin
lipid layer provided high cell uptake and aqueous
solubility, biocompatibility and stability. Fifth,
cell-based experiments demonstrated rapid particle
uptake, retention, and antiretroviral efficacy in target
macrophages. Particle uptake remained constant from
4 to 8 hours possiblely due to cells reaching their
capacity or exocytosis at later times. Macrophages
rapidly internalized rod-shaped nanoparticles
compared to spherical particles.[48, 69, 70] Because
the uptake mechanism used by the macrophages was
phagocytosis, shape, size, surface properties as well as
quantity of particles played a significant part in
uptake.[48, 50, 69, 70] The eight days of antiretroviral
efficacy exhibited by BSNR-RPV accords with similar
studies that found between 5 and 20 days of
protection with NRPV.[71] Provided that on average
more than 1 microgram was retained per million cells,
which positively correlated with bismuth intracellular
concentrations, it can be surmised that RPV depots
http://www.thno.org
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were maintained until our assay’s terminus.
Numerous reports characterize RPV's potency in the
sub-nanomolar range. [71, 72] Therefore, the
equivalent levels of long-term protection regardless of
treatment concentration in our work may be
explained in that macrophages treated with low- and
high-dose
BSNR-RPV
maintained
drug
concentrations above RPV's 50% maximal effective
concentration (EC50) for at least eight days. Sixth,
particles’ use as a multi-modality agent was
confirmed by both SPECT, LA-ICP-MS, ICP-MS and
UPLC-MS/MS in mice. Such imaging allowed, for the
first time, sub-organ localizations in live animals with
a high degree of sensitivity and specificity, exceeding
those acquired by conventional magnetic resonance
imaging (MRI).
In recent years, the development of bismuth
nanorods, nanoparticles, nanodots, and nanoplates
has been described for a wide range of biomedical and
bioimaging applications.[28, 73, 74] These include
therapeutics and drug delivery for metabolic,
inflammatory, and cancerous diseases and use as
biosensors, photothermal and contrast agents.[75-78]
While the field of BSNRs theranostics remains in its
infancy, the primary challenge in next step
applications rests in enhancing radiolabeling
efficiency
and
drug
loading.
Notably,
non-radiolabeled BSNRs have been successfully used
as imaging agents as “bismuth” has an ultrahigh
X-ray attenuation coefficient (bismuth, 5.74 cm2/g−1 at
100 keV).[27, 79] High blood and renal concentrations
of bismuth ions are considered safe.[80-83] Bismuth is
considered one of the most biocompatible metals
having been widely employed as an anti-diarrheal
(bismuth subsalicylate); an antimicrobial (for
eradication Helicobacter pylori, Pseudomonas aeruginosa,
Burkholderia multivorans and B. cenocepacia); and as an
antidote for cadmium poisoning.[84] The precursor
chemicals of BSNRs synthesis are comparatively
inexpensive compared to other metals, such as gold
and platinum.[85] Bismuth and sulfur components
easily undergo oxidative decomposition to soluble
bismuth (III) species under physiological conditions
and show considerable lipophilicity and membrane
permeability, as such, differ substantively from other
metal particles.[86, 87] Our results demonstrate that
particle shape influences particle distribution in
regional zones of spleen. This indicates that
177LuBSNRs readily accumulate in lymphoid organs,
including gut, indicating the rapid migration and
deposition of particles in these organs where
maximum number of HIV-1 are present. This
observation matched SPECT results that indicated
highly particle uptake and deposition in tissues with
large numbers of macrophages and other immune
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cells. Such multifunctional imaging (177LuBSNRs) and
therapeutic particles (NRPV) will facilitate rapid
screening of antiviral drug tissue distribution.
Each imaging technology that was or can be
employed in future research has its own inherent
limitations.[88] Information attained from single
imaging modality tracking nanoparticles typically
cannot satisfy the requirement to directly visualize
infection sites and quantify the amount of drug at
those sites. Hence, combination of more than two
imaging modalities into a single particle, known as an
“all-in-one” nanostructure, allows for spatial
temporal assessments of virus replication sites. SPECT
generates
real-time,
high-resolution
3D
reconstructions.[89, 90] The SPECT bimodality
imaging
of
lymphoid
organs
with
lipid/calcium/phosphate (LCP) nanoparticles grafted
with 111In has been reported.[91] Similarly, recent
reports demonstrate that bismuth nanocrystals
encapsulated in PLGA particles can be used
effectively as a CT contrast agent.[92] Lipid coating on
the BSNRs facilitates such use as it prevents
aggregation
in
physiologic
conditions.[93-95]
Considering these advantages, SPECT imaging
through
radiolabeled
BSNRs
allows
direct
visualization of tissue sites of viral replication,
providing a notable advantage for finding where
residual virus may hide from immune surveillance
mechanisms.[96, 97, 98] Interestingly, BSNRs
concentrations were found in spleen at higher levels
than in the liver. The extensive metabolism in liver
may facilitate more rapid organ clearance for BSNRs
compared to spleen.[99] Finally, the decomposition of
BSNRs in liver due to plasma proteins on the surface
of particles may also facilitate clearance.[100, 101]
Liver metabolism of our BSNRs particles could
result in the leaching of particle components that
include free 177Lu. This concern coupled with signals
observed in or near bones plates in later evaluated
time points could affect experimental results. [102]
Nonetheless, we affirmed the specificity of the SPECT
data as popliteal and axillary lymph nodes and bone
were independently dissected and subjected to
gamma scintillation analysis. These data sets further
confirmed the SPECT specifically and both assays
were concordant. Thus, while release of 177Lu ions
may occur its effects on the overall interpretation of
particle-drug biodistribution is limited.
Our analyses revealed that BSNR-RPVs could
serve as a predictor for RPV drug levels and
effectiveness. In fact, 5 days after injection, SPECT
signal and RPV concentration were correlated
strongly, one with the other (r = 0.8676). In spleen,
RPV correlated with bismuth concentration, gamma
scintillation counts, and SPECT signal (r = 0.9412,
http://www.thno.org
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0.8361, and 0.5593, respectively). In lymph nodes,
SPECT signal correlated with RPV concentration on
day 2 (r = 0.6936). We observed an even stronger
correlation between SPECT signal and RPV
concentration on day 5 (r = 0.9278). Day 5 lymph node
SPECT signal also correlated with bismuth
concentration (r = 0.7283), providing evidence that the
SPECT signal could be used to predict RPV or
bismuth biodistribution in a treated animal.
LA-ICP-MS imaging is a powerful tool for
providing sub-organ distribution information,
enabling greater insight into the biological fate of
nanoparticles. The quantitative capability of such
imaging assays also facilitates delivery optimization
by providing comparative formulation metrics.[103,
104, 105] The use of laser ablation allows monitoring
of each tissue type with resolutions between 25 to 50
µm demonstrating cell nanoparticle distributions.
When properly configured, LA-ICP-MS can image the
distributions of nanoparticles with core diameters of 2
nm
present
at
low
parts-per-billion
concentrations.[106] Because bismuth has a very low
biological background, the BSNRs are an almost ideal
nanomaterial for fully exploiting the resolution
capabilities of LA-ICP-MS.
In conclusion, we have demonstrated the
feasibility of theranostics for studies of LA ARV
biodistribution and activity. Using both SPECT and
LA-ICP-MS analyses 177LuBSNRs were shown to be a
viable tool to monitor the distribution and transport
or ARVs and in particular RPV to macrophage rich
lymphoid tissues and liver. The PK and
biodistribution patterns obtained with particle are
comparable to therapeutic particles now being
employed in treatment paradigms for HIV-1
infection.[24, 33] Moreover, the results were cross
validated by statistical models providing a framework
for predictive assessments of LA ARVs distribution
and activities in an infected human host.

Experimental section
Reagents and chemicals
Bismuth neodecanoate (Bi(OCOC(CH3)2(CH2)5
CH3)3), thioacetamide (CH3CSNH2), oleic acid,
oleylamine, L--phosphatidylcholine (PC) (from egg
yolk), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), were obtained from Sigma
Aldrich, St. Louis, MO, USA. Corden Pharma
International (Plankstadt, Germany) supplied the
1,20-distearoyl-phosphatidylethanolaminemethylpolyethyleneglycol conjugate 2000 (DSPE-PEG2000).
Hangzhou Bingo Chemical Co., Ltd. (Hangzhou, ZJ,
China) provided the rilpivirine (RPV). Lutetium (III)
chloride, anhydrous, 99.9% (LuCl3) was received from
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Alfa Aesar, Haverhill, MA, USA. 177Lutetium chloride
(177LuCl3) in 0.05 M HCl, mass = 3.0 µg was requested
and delivered from Oak Ridge National Laboratory,
Oak Ridge, TN, USA. Pluronic F 108 Pastille (P338)
was bought from BASF, Florham Park, NJ, USA.
Agilent Technologies, (Santa Clara, CA, USA) was the
source of the monoclonal mouse HIV-1 p24 (Clone
Kal-1) and Dako EnVision+ detection system HRP
labeled polymer anti-mouse antibodies used in this
paper. [33, 35, 71] Leukapheresis was performed on
HIV-1,2 and hepatitis B seronegative donors and
human peripheral blood monocytes were obtained
and purified by countercurrent centrifugal elutriation.
Monocytes were differentiated into macrophages
according to our previously published protocols. [24,
35, 33, 71]

Animals
Male Balb/cJ mice (6-7 weeks old) were
purchased from Jackson Laboratories (Bar Harbor,
Maine, USA). Animals were housed in the University
of Nebraska Medical Center (UNMC) Comparative
Medicine animal facility according to the Association
for Assessment and Accreditation of Laboratory
Animal Care guidance. The UNMC Institutional
Animal Care and Use Committee approved all
protocols related to animal experiments and were
certified to have met the requirements and ethical
guidelines set forth by the National Institutes of
Health in handling laboratory animals for research.

Preparation of rilpivirine (RPV) freebase and
manufacture of nanoformulated RPV (NRPV)
RPV
freebase
was
prepared
then
nanoformulated as previously described. [33, 71]
Nanoformulated RPV (NRPV) was manufactured
using an Avestin EmulsiFlex-C3 high-pressure
homogenizer. Briefly, Pluronic 338 (P338) and RPV
free-base were dispersed in water at concentrations of
0.5% and 1% (w/v), respectively, and mixed (400-600
rpm) overnight at room temperature. Presuspensions
were homogenized at 20,000 psi until homogeneous
nanocrystals in terms of size (nm) and polydispersity
(PDI) were produced. NRPV was purified and
concentrated
by
centrifugation.
Specifically,
nanoformulations were centrifuged at 5,000 x g for 5
minutes, at which point supernatants were subject to
a second spin of 10,000 x g for 5 minutes. Resultant
pellets were resuspended in endotoxin free water. A
final centrifugation step of 200 x g for 3 minutes
removed any aggregated particles. NRPV (size: 341.8
± 4 nm, PDI: 0.22 ± 0.03, zeta potential: -9.06 ± 0.4 mV)
was characterized by dynamic light scattering and
assayed for drug content (56.8 mg/ml) by
UPLC-UV/Vis using previously described methods.
http://www.thno.org
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[33, 71] To test drug loading content, NRPV was
frozen at -80˚C and lyophilized to yield a dry powder.
Samples were weighed, dissolved in methanol, and
analyzed by UPLC-UV/Vis. Drug loading was
calculated by the following equation. Drug loaded (%)
= (Weight of drug in lyophilized formulation/weight
of lyophilized formulation) X100.

Preparation of intrinsically radiolabeled
177LuBSNR particles
Intrinsically radiolabeled 177LuBSNRs particles,
were prepared by a solvothermal technique.[26, 28] A
typical reaction scheme is available in the
Supplementary Figure S1 top panel (imaging
particles). Bismuth neodecanoate (290 mg, ~400 µM)
and 4 mL of oleic acid (OA) were mixed in a glass vial
and stirred for 10 min. Subsequently, ~ 1665 MBq (~45
mCi) of 177LuCl3 and 4 mL ethanol were mixed in a
separate vial and transferred to the bismuth-oleic acid
(Bi-OA) mixture. In a 1.5 mL microcentrifuge tube,
thioacetamide (30 mg, ~ 400 µM) was quickly added
to 800 µL of oleyl amine (OAm) and the mixture was
sonicated for 15 minutes to completely dissolve the
mixtures. After vigorous stirring for 30 minutes, the
colloidal dark black solution was transferred into a
250 mL high safety Teflon-lined reactor that was
placed in a stainless-steel autoclave reactor, sealed
airtight, and heated at 150°C for 10 hours. The
systems were then allowed to naturally cool to room
temperature (around 12 hours). After reaching room
temperature, the reactor was opened in a controlled,
radioisotope work station. Fifty milliliters of ethanol
were added followed by vortexing and sonication.
The solution was then centrifuged at 976 xg for 30
minutes at 15°C. 177LuBSNR particles were collected
and purified by repeating the same ethanol washing
process three times to remove non-reacted
components. Radioactivity of 177LuBSNRs was
measured by gamma counter (CRC®-25R dose
calibrator, Capintec, Inc, Florham Park, NJ, USA).
Lipid coated 177LuBSNR particles were prepared by
the thin-film dispersion technique. First, 100 mg
L-α-phosphatidylcholine and 50 mg DSPE-PEG2000
were dissolved in a chloroform/hexane mixture (5:1
v/v) contained within a round-bottomed flask and
evaporated to form a thin film using a rotavap
(Heidolph, Hei-VAP Precision; G3B Vertical, USA).
The films were dried under vacuum overnight (18
hours) to ensure the complete removal of organic
solvents. Second, 177LuBSNRs (50 mg particles; ~ 647.5
MBq = ~ 17.5 mCi) were dispersed in cyclohexane (2
mL) followed by bath sonication for 10 minutes to
achieve a uniform dispersion of the particles in the
solvent. The 177LuBSNRs-cyclohexane dispersion was
mixed with 2 mL of 2% (v/v) Tween-80 in a 25 mL
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round-bottom flask and sonicated for 5 minutes to
form a turbid metalosome emulsion. Third,
cyclohexane
was
removed
from
the
177LuBSNRs/cyclohexane/Tween-80
emulsion by
rotavaporation. Lastly, the 177LuBSNRs particle
solution was transferred to the lipid film coated
round-bottomed flask and dispersed in the lipid film
through gentle rotation at 45°C with continuous bath
sonication. The end product was collected by
centrifugation at 270 xg for 10 minutes. 177LuBSNRs in
the supernatant was used for particle size and
radioactivity analyses. Non-radiolabeled LuBSNRs
and drug loaded particles were synthesized by the
same technique except that non-radioactive 175LuCl3
was used instead of 177LuCl3. BSNRs-RPV particles
were prepared with 10 mg of RPV drug in the lipid
film. NRPV suspensions were prepared as described
previously (supplementary Figure S1 bottom panel
and SM2).[33]

Particle characterizations
The morphology, lattice crystal structure,
elemental composition, and chemical color mapping
of the synthesized BSNRs and 177LuBSNRs particles
were determined by bright field high-resolution
transmission electron microscopy (HR-TEM), selected
area electron diffraction (SAED), energy-dispersive
x-ray spectroscopy (EDX), and scanning transmission
electron microscopy (STEM) with high-angle annular
dark-field (HAADF) (FEI Tecnai Osiris S/TEM
operated at 200 kV). The TEM samples were prepared
in cyclohexane and dried on a copper grid
(FCF-400-CU, Electron Microscopy Sciences–EMS,
Hatfield, PA, USA) at room temperature. Bright field
images were taken with exposure times of 0.5 s. No
staining of particles was used, since the heavy metal
contrast was adequate for imaging. The additional
gain in speed can also be used to collect EDX
elemental mappings from a larger field-of-view. The
lattice fringes of the obtained samples and the
corresponding SAED patterns were examined using
HR-TEM at 200 kV. The experimental SAED patterns
were analyzed using PCED2 software (Landyne
Software, Lincoln, NE, USA).
To determine the shape and size of NRPV
particles, the nanosuspension was vortexed and the
samples were placed onto a Whatman Nuclepore
Track-Etch membrane filter, mounted to the
conductive adhesive tape on the scanning electron
microscope (SEM) stub, and air-dried overnight. After
sputter-coating with a thin layer (~5 nm thick) of
chromium using Denton Desk V sputter, the sample
was examined with a Hitachi S4700 field-emission
SEM. For transmission electron microscopy (TEM),
the NRPV particles suspensions were collected using
http://www.thno.org
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carbon-formvar coated grids and stained with 1%
phosphotungstic acid. Samples were examined and
imaged using a Hitachi H7500 TEM. The particles
were also characterized by Wavelength Dispersive
X-ray Fluorescence (WDXRF) analysis using a Rigaku
WDXRF (Supermini200) spectrometer with high
resolution and lower detection limits for elemental
analysis. A 200 W, air cooled, Pd X-ray source was
operated at 50 kV and 4 mA to produce the excitation
spectrum with faster elemental detection capability. A
three-crystal analyzing unit was equipped in the
system to support the standard LiF (200), PET, and
RX25 crystals for the detection of the elements
ranging from ultrafiltration (UF). Particle surface
chemistry analysis was performed with X-ray
photoelectron spectroscopy (XPS) and measurements
were carried out using monochromatic Al Kalpha
x-ray with an energy of 1486.6 eV by Thermo
Scientific K-alpha+XPS (Thermo fisher scientific,
Waltham, MA, USA). Powder X-ray diffraction (XRD)
analyses of BSNRs, 177LuBSNRs and NRPV were
performed in the 2θ range of 2–70° using a
PANalytical Empyrean diffractometer (PANalytical
Inc.; Westborough, MA, USA) with Cu-Kα radiation
(1.5418 Å) at 40 kV, 45 mA settings. A mask of 20 mm
and divergence slit of 1/32° were used on the incident
beam path. A thin layer of the particle powder sample
was placed on a zero-background silicon plate and the
sample holder was continuously spun at the rate of
22.5 deg/s during all measurements. The PIXcel3D
detector, equipped with a beam monochromator,
(PANalytical Inc.; Westborough, MA, USA) was
scanned at a rate of 0.053 deg/s. Atomic Force
Microscopy (AFM) images were collected with a
Nanoscope IV system (Bruker Nano Surfaces, Santa
Barbara, CA, USA) in Tapping Mode at ambient
conditions. Silicon probes RTESPA-300 with a
resonance frequency of ~300 kHz and a spring
constant of ~40 N/m were used for imaging at a
scanning rate of 2.0 Hz. Image processing and particle
size analyses were performed using Femtoscan
software (Advanced Technologies Center, Moscow,
Russia). Particle sizes of the BSNRs and NRPV was
determined by measuring hydrodynamic diameter
and particle size distribution in water on a Malvern
Nano-Series Zetasizer system (Malvern Instruments
Ltd., Malvern, UK). Excitation and emission spectra of
BSNRs
were
determined
using
UV
spectrophotometry (SpectraMax® M3, Molecular
Devices, LLC, San Jose, CA, USA). RPV content of
BSNRs-RPV and NRPV was determined by
reverse-phase
ultra-performance
liquid
chromatography (UPLC) using a Waters Acquity
UPLC H-Class System with TUV detector and
Empower 3 software (Waters, Milford, MA, USA) as
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previously described.[33, 71] Bismuth and sulfur
quantifications were performed by inductively
coupled plasma mass spectrometry (ICP-MS) at the
University of Nebraska-Lincoln’s Spectroscopy and
Biophysics Core Facility, using an Agilent 7500cx
ICP-MS (Santa Clara, CA, USA) coupled with a
96-well plate autosampler Model SC/DX4 from
Elemental Scientific, Inc. (Omaha, NE, USA),
operating in Mix-Gas collision/reaction mode (3.5 mL
H2 and 1.5 mL He per minute). Other conditions
were: plasma power, 1500 W; carrier gas flow, 1
L/minute; makeup gas flow, 0.15 L/minute; sample
depth, 8 mm; plasma gas, 15 L/minute. The
concentrations were calculated against an external
calibration curve with 50 μg/L of Ga used as internal
standard (IS) throughout (71Ga isotope). Tissue
samples were suspended in 4 times the volume of
metal-grade nitric acid, incubated at room
temperature for up to 2 hours followed by overnight
digestion at 65oC. The samples were cooled and
diluted 20-fold into the autosampler at a final
concentration of 10 mg/mL.

Drug loading for BSNRs
BSNRs-RPV formulations were prepared by
using a similar technique as for lipid coating of
177LuBSNRs. First, 10 mg of RPV free base was added
to a glass vial and completely dissolved in methanol
with sonication for 10-15 minutes. Second, 100 mg
L-α-Phosphatidylcholine and 50 mg of DSPE-PEG2000
were placed in a round bottom flask, chloroform and
hexane were added along with RPV in same flask. The
solvent was removed by rotavaporation to create a
uniform thin lipid film. The film was left to dry in a
desiccator vacuum overnight to ensure the removal of
any trace solvent. Third, 100 mg of 177Lu/BSNRs
particles were dispersed in cyclohexane and sonicated
for 30 min until completely mixed. Then, 10 mL of 2%
(v/v) tween 80 was added and the mixture was
sonicated to form a turbid emulsion. Fourth,
cyclohexane was removed by rotavaporation and
afterwards, particles were transferred into the round
bottom flask with RPV-lipid film for coating process.
The flask was steadily rotated in warm water with
gentle sonication to ensured complete dissolution and
coating of lipid film. The BSNRs-RPV particles were
purified by centrifugation of the suspension at 270 xg
(500 rpm) for 10 minutes. Supernatant containing
particles was used for particle size, drug loading
quantitation and radioactivity analysis. Metal content
was analyzed by ICP-MS. For drug quantification
from nanoparticles, ~50 mg of lyophilized
nanoparticles was dissolved in 10 mL of DCM:
methanol (1:1 v/v) mixture. The mixture was then
bath sonicated for 30 minutes followed by
http://www.thno.org
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centrifugation at 35,1315× g for 30 minutes. The
supernatant was collected and DCM was evaporated
at room temperature. The drug in methanol was
quantified by UPLC-UV/Vis.[24]

Radiolabeled particle stability
The in vitro stability of 177LuBSNRs was
determined in phosphate-buffered saline (PBS) and
rat plasma. Briefly, 100 L of 177LuBSNRs (1.85 Mbq =
~50 Ci) were incubated in 1.5 mL of PBS or rat
plasma at 4C or 37C for up to 72 hours. After 0, 24,
48, and 72 hours, the samples were centrifuged at
2,0817 xg for 30 minutes at 10C (Refrigerated
Centrifuge 5417R, Eppendorf North America,
Hauppauge, NY, USA). The supernatant was
collected into a separate microcentrifuge tube. The
radioactivity in the pellet and the supernatant were
measured by gamma counter. To determine percent
stability the following equation was used;
Radiolabeling stability (%) = radioactivity in
pellet/total radioactivity (pellet plus supernatant).[33]

Macrophage uptake and retention of particles
The uptake and retention of BSNRs-RPV
particles were evaluated in human monocyte-derived
macrophages (MDM) following previously published
protocols. [24, 33, 35] Briefly, 1.5 x 106 human
monocytes were seeded into 12-well polystyrene
tissue culture plates and incubated in Dulbecco’s
Modified Eagles Medium containing macrophage
colony stimulating factor for seven days at 37C to
promote cell differentiation into macrophages
(MDM).[24, 33, 35] To determine uptake, MDM were
treated with BSNRs-RPV at a concentration of either
12.5 g/mL or 25 g/mL (bismuth content) for 2, 4, 6,
or 8 hours. To determine cell retention, MDM were
treated with either 12.5 g/mL or 25 g/mL
BSNRs-RPV for 8 hours. The treatment media was
removed, cells were washed three times with PBS,
and treatment-free media was added. Bismuth and
RPV content in cells were determined at 1, 2, 3, and 5
days following treatment with half media exchanges
every other day to maintain cell viability. For both
uptake and retention, at the specified time points,
media was removed, cells were washed three times
with PBS, harvested, and counted, following
centrifugation at 450 xg for 10 minutes. Cell pellets
were stored at -20C until analysis. For metal analysis,
the cell pellet was dissolved in fresh diluted nitric
acid. Bismuth concentration was determined by
ICP-MS and reported as µg/106 cells. For RPV
analysis, 100 L of methanol was added to the cell
pellet followed by 15 seconds of sonication. The
mixture was then centrifuged at 450 xg for 10 minutes
and the supernatant collected and analyzed by

650
UPLC-MS/MS for RPV content.[24, 33, 35]
Cell changes associated with uptake of BSNRs
were assessed by TEM, AFM and confocal
microscopy, taking advantage of BSNRs intrinsic near
infrared (NIR) fluorescence properties. For confocal
studies, MDM were cultured on glass coverslips in 12
well plates at a density of 1.5 x 106 cells/well. MDM
were then treated with 25 g/mL BSNRs (as bismuth)
for 8 hours. After particle incubation, treatment media
was removed and cells were washed three times in
cold PBS. After washing, the cells were fixed with
ice-cold 4% paraformaldehyde (PFA) in PBS at room
temperature for 30 minutes. Glass coverslips with
fixed cells were then transferred to glass slides. Cell
nuclei were stained with ProLong Gold AntiFade and
4’6-diamidino-2-phenylindole (DAPI, Thermo-Fischer
Scientific, Waltham MA, USA) and images acquired
using a 63x oil objective on an LSM 710 confocal
microscope (Carl Zeiss Microimaging, Inc., Dublin,
CA, USA) interfaced with Image Browser AIM
software (version 4.2). NIR imaging of particle uptake
by MDM was performed on an Olympus IX73
inverted microscope with a xenon excitation source
and equipped with an Olympus DP80 Digital Camera
and cellSens Dimension software. Unstained slides
were imaged for autofluorescence with a FITC filter
cube, and NIR fluorescence with an ICG filter cube.
Emission wavelengths were; DAPI: 455 nm;
TexasRED: 615 nm; ICG: 767 nm. For uptake analysis
by TEM, cells were scraped, collected from wells, and
fixed in 0.1 M Sorenson’s phosphate buffer (pH 6.2)
containing 2% glutaraldehyde and 2% w/v PFA for 24
hours at 4C. TEM sample preparation, staining, and
imaging were performed according to previously
published protocols.[24, 35]
Visualization of the surface topography of
BSNR-loaded MDM was evaluated using AFM.
Coverslips with fixed cells were removed from wells
and mounted on a slide. Images were acquired in the
air using an MFP-3DTM system (Asylum Research,
Santa Barbara, CA, USA) operating in tapping mode.
AFM probes MSNL-F with a nominal spring constant
of ∼0.6N/m were used for imaging. Image processing
was performed using Femtoscan software (Advanced
Technologies Center, Moscow, Russia).[33]

Assessment of antiretroviral activities
Antiretroviral activities of BSNRs-RPV were
evaluated by measures of HIV reverse transcriptase
(RT) activity in cell culture medium and HIV-1 p24
antigen staining of cells and compared to the
antiretroviral activity of NRPV as previously
described with the following modifications.[33] First,
MDM were treated with 12.5 µg/mL or 25 µg/mL
(bismuth concentration) for 8 hours. Second, cells
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were challenged with HIV-1ADA at a multiplicity of
infection (MOI) of 0.1 infectious virions per cell for 16
hours on day 1, 3, 5, or 8 after treatment removal.
After an additional 10 days, culture supernatant was
removed from cells and assessed for progeny virion
production by RT activity.[33] The cells were fixed
with 4% PFA for 15 minutes at room temperature and
then stained with antibodies against HIV-1 p24 as
previously described.[13, 20, 24, 33] Images were
analyzed using a Nikon TE300 microscope with a 20 X
magnification objective.

Tissue biodistribution of particles
To determine whether BSNRs could predict ARV
biodistribution, we designed an in vivo experiment
comprised of six different treatment groups of 15
Balb/c mice per group (10 mice for group 5). Each
group received treatment as a single intravenous
injection on the first day of the experiment. As shown
in Table 3 and supplementary Figure S12, the first
and second groups received NRPV at a dose of 45
mg/kg (G1) and 5 mg/kg (G2), respectively. Group 3
received both BSNRs (80 mg/kg, bismuth) and NRPV
(45 mg/kg) (G3). RPV loaded BSNRs (BSNRs-RPV)
were administered to the fourth group (G4) at a dose
of 80 mg/kg bismuth, (~5 mg/kg RPV). Group 5 (G5)
received 80 mg/kg bismuth as 177LuBSNRs (37 MBq =
~ 1000 µCi) for SPECT imaging. The sixth group (G6)
received non-radioactive BSNRs at a dose of 80
mg/kg bismuth.
For G1 and G2, which received only NRPV,
plasma was collected on days 1, 2, 3, 4, 7, 14, 21, and
28 and analyzed by UPLC-MS/MS for RPV content.
Out of 15 mice, 5 each were sacrificed and internal
organs collected on days 2, 5, and 28. These tissues
were analyzed by UPLC-MS/MS for RPV content. G3
and G4, which received BSNRs plus NRPV or
BSNRs-RPV, respectively, underwent similar plasma
and tissue collection and RPV analysis as G1 and G2,
however, plasma and tissue were also analyzed by
ICP-MS for bismuth content. G5 received 177LuBSNRs
and SPECT imaging was performed on these animals
at 6, 12, 24, 48, and 120 hours (5 days) post-injection.
Acquired images were reconstructed to 3D renditions
and regions of interest (ROIs) were drawn over
various
organs
to
determine
radioactivity
concentration in counts per minute (CPM)/mm3
tissue. On days 2 and 5 post-injection, 5 animals were
sacrificed and liver, spleen, heart, lungs, brain,
muscle, blood, bone, lymph nodes, stomach, pancreas,
small intestine, large intestine, bladder, testes,
kidneys, and tail (injection site) were collected. These
organs along with the animals’ bedding (excreted
radioactivity) and carcasses were subjected to gamma
counting (gamma scintillation spectrometry (Ortec
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NaI(Ti) Scintillation Radiation Detector, Ametek, Oak
Ridge, TN, USA) and percent injected dose per gram
of tissue (%ID/g) was determined. G6, which
received non-radioactive BSNRs, had tissues collected
on days 2, 5, and 28. Samples were analyzed for
bismuth content by ICP-MS.
Various parameters were assessed across groups
and time to determine the predicative value for
long-term biodistribution. Pearson’s correlation
coefficients for two parameter comparisons were
determined for RPV concentration, bismuth
concentration, ROIs (SPECT) measurements, as well
as gamma counter radioactivity measures in liver,
spleen and lymph nodes. Means of absolute “r”
values with p ≤ 0.05 were used to create the “multiple
ribbon bar graph” to summarize the closed correlation
groups by including time, dose, treatments, and
measurements of particle components.

SPECT and gamma scintillation
determinations biodistribution
SPECT imaging was performed on G5 mice to
assess the in vivo biodistribution of 177LuBSNRs. Each
animal received ~1000 Ci of 177LuBSNRs (~ 80
mg/kg bismuth). Images were acquired at 6, 12, 24,
48, and 120 hours post injection using a SPECT/CT
system (Flex Triumph, TriFoil Imaging, Northridge,
CA, USA) fitted with a five pinhole (1.0 mm per
pinhole) collimator. First, CT images were acquired
using 360 projections over 360° with an X-ray tube
current of 140 mA and voltage of 75 kilovoltage peak
(kVp) at a magnification of 2.0 (field of view = 59.2
mm2). Immediately after, SPECT image acquisition
was performed with the following parameters; 64
projections at 15 second per projection over 360° using
a radius of rotation of 48 mm (field of view = 59 mm2).
Co-registration of anatomical CT images and
functional SPECT was performed by 3D visualization
and analysis software, VivoQuant 3.5 (Invicro Boston,
MA, USA). ROIs were drawn over various organs and
radioactivity content and organ volume were
determined to calculate counts per cubic millimeter
(mm3). After days 2 and 5 scans, mice were sacrificed
and various organs including heart, lungs, liver,
pancreas, stomach, spleen, small intestine, large
intestine, kidneys, bladder, lymph nodes, muscle,
bone, brain, testes, injection site (tail), remaining
carcass and blood were collected, weighed, and
analyzed ex-vivo for radioactivity using gamma
counter scintillation spectrometry (ORTEC NaI(Ti)
Scintillation Radiation Detector, Ametek, Oak Ridge,
TN, USA). Additionally, animals were individually
caged so that excreted signal could be measured from
the bedding. Signal measured was back-calculated to
the time of injection to account for radioactive decay
http://www.thno.org
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of 177Lu (t1/2 = 6.64 days).[33] The signal from each
tissue was normalized to the sum of total counts from
all sources and then divided by the weight of the
organ to obtain % ID/g for each tissue.

Laser ablation inductively coupled plasma
mass spectrometry (LA-ICP-MS)
After G3, G4 and G6 animals were sacrificed,
spleens were collected for LA-ICP-MS analysis.
Spleen processing and imaging analysis were
completed as described previously.[38, 107] In brief,
frozen spleens were sliced to a thickness of 20 μm
using a LEICA CM1850 cryostat and placed on glass
slides for either LA-ICP-MS imaging or hematoxylin
and eosin staining. The staining was performed using
a rapid Chrome frozen section staining kit (Thermo
Fisher Scientific, Waltham, MA, USA). For
LA-ICP-MS, a CETAC LSX-213 G2 laser system and a
Perkin Elmer Nexion 300X ICP-MS were used. The
parameters used in the laser ablation system were the
following: spot size = 50 μm, scan rate of 15 μm/s, 10
Hz laser frequency, 10 s of shutter delay, and a carrier
He gas flow of 0.6 L/minute. The ICP-MS parameters
were the following: nebulizer argon flow rate = 0.7
L/minute, plasma argon flow rate = 16.5 L/minute,
auxiliary argon flow rate = 1.4 L/minute, analog stage
voltage = -1650 V, and pulse stage voltage = 1000 V.
Three elements were detected, including bismuth,
iron, and zinc. Images were reconstructed and
analyzed in a custom script written in Python that
uses multiple metals to identify sub-organ regions of
interest. In short, the script uses statistical k-mean
clustering to distinguish the red pulp, white pulp, and
marginal zones in the spleen, enabling a relative
measure of bismuth in each sub-organ region.

Autoradiography
Livers and spleens were excised at 2 and 5 days
post-injection from mice treated with 177LuBSNRs
(G5). Collected tissues were washed with deionized
water and immediately embedded into optimal
cutting temperature (O.C.T) compound (Fisher
HealthCare, Waltham, MA, USA). Cryostat sections
(10 μm) of tissue samples were prepared and exposed
to a phosphor screen overnight in the dark (Leica
CM1850, Leica Biosystems Inc, Buffalo Grove, IL,
USA). The phosphor screen was subsequently imaged
by a Typhoon FLA 9500 variable mode imager (GE
Lifesciences, Pittsburg, PA, USA) at 25 μm resolution.

UPLC-MS/MS analysis of drug in plasma and
tissues
Plasma
samples
were
prepared
for
UPLC-MS/MS analysis for RPV content according to
our previously published work. [33, 71] In brief, 10 µL
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of internal standard (IS) solution (250 ng/mL
indinavir and 500 ng/ml lopinavir; final
concentration 25 ng/ml indinavir, 50 ng/ml
lopinavir) was added to 25 µl of plasma along with 1
mL of ice-cold MS -grade acetonitrile. After vortexing
and centrifugation, supernatants were evaporated
and then reconstituted in 100 µL 50% (v/v) methanol
in water. For tissue analyses, 100 mg of tissue was
homogenized in 4 volumes of 90% (v/v) methanol in
water. Standard curves were prepared in blank mouse
plasma or tissue in the range of 0.2–2000 ng/mL RPV
with 10 µL of IS added. An ACQUITY UPLC-BEH
Shield RP18 column (1.7 µm, 2.1 mm x 100 mm) was
used for chromatographic separation of 10 µL of
plasma or tissue samples using a 7-minute gradient of
mobile phase A (7.5 mM ammonium bicarbonate in
Optima-grade water adjusted to pH 7 using acetic
acid) and mobile phase B (100% Optima-grade
methanol) at a flow rate of 0.25 mL/minute. For more
exact details please see our previously published
work. [33, 71]

Bismuth quantitation
Bismuth concentrations in plasma and tissues
were determined in mouse plasma and tissues by
ICP-MS metal at the University of Nebraska-Lincoln's
Spectroscopy and Biophysics core facility.[33]

Tissue localization and toxicity
Particle distribution within the spleen and liver
from mice treated with BSNRs (G6) was evaluated via
TEM. For TEM examination, tissue samples were
fixed in TEM buffer at room temperature. Tissue
processing and sectioning were performed as
previously described.[24] In vivo toxicity of
BSNRs-RPV was determined by histological
examination.
Here,
5
m
sections
of
paraffin-embedded tissues were fixed on glass slides
and stained with H&E. Images were captured using a
Nuance EX multispectral imaging system affixed to a
Nikon Eclipse E800 microscope (Nikon Instruments,
Melville, NY, USA) fitted with a 20X objective.
Histopathological assessment was conducted in
accordance with the guidelines of the Society of
Toxicologic Pathology. Serum chemistry was assessed
using a VetScan comprehensive diagnostic profile
disc and a VetScan VS-2 instrument (Abaxis
Veterinary Diagnostics, Union City, CA, USA).[24, 33,
35]

Statistical analyses
For all studies, data were analyzed using
GraphPad Prism 8.2 software (GraphPad, La Jolla,
CA, USA) and are presented as the mean ± standard
error of the mean (SEM). Experiments with multiple
http://www.thno.org
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time points were analyzed using two-way factorial
ANOVA and Bonferroni's post hoc tests for multiple
comparisons. Pearson’s correlation analyses were
performed for multiple tissues, doses, and data
acquisition times from SPECT, ICP-MS and
UPLC-MS/MS. Two-parameter comparisons yielding
a Pearson coefficient greater than 0.5 (r > 0.5) were
considered of predictive value.

Abbreviation
177Lu: 177Lutetium
177LuBSNRs: 177Lutetium-bismuth

sulfide nanorods
AFM: atomic force microscopy
ART: antiretroviral therapy
ARV: antiretroviral drugs
Bq: becquerel
BSA: bovine serum albumin
BSNRs: bismuth sulfide nanorods
BSNRs-RPV: bismuth sulfide nanorods rilpivirine
Ci: curie
DAPI: 4’6-diamidino-2-phenylindole
DCM: dichloromethane
DMSO: dimethyl sulfoxide
DSPE-PEG2000:
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene
glycol)-2000]
EC50: 50% maximal effective concentration
GALT: gut-associated lymphoid tissue
HIV-1: human immunodeficiency virus type 1
HR-TEM: high-resolution transmission electron
microscopy
IV: intravenous
IM: intramuscular
kVp: kilovoltage peak
LA ARV: long acting antiretroviral drugs
LA-ICP-MS: laser ablation inductively coupled
plasma mass spectrometry
LA NRPV: long acting nanoformulated rilpivirine
LASER ART: long acting slow effective release
antiretroviral therapy
MBq: mega becquerel
MDM: human monocyte-derived macrophage
MOI: multiplicity of infection
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NanoART: nanoformulated antiretroviral therapy
NIR: near Infrared
NRPV: nanoformulated rilpivirine
OA: oleic acid
OAm: oleyl amine
PBS: phosphate-buffered saline
PC: phosphatidylcholine
PD: pharmacodynamics
PDI: polydispersity index
PFA: paraformaldehyde
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PK: pharmacokinetic
RB: round-bottom flask
ROI: region of interest
RPV: rilpivirine
RT: reverse transcriptase
SAED: selected area diffraction
SEM: scanning electron microscope
SPECT:
single
photon
emission
computed
tomography
STEM: Scanning transmission electron microscopy
TEM: transmission electron microscopy
μCi: microcurie
UPLC-MS/MS: ultra-performance liquid chromategraphy tandem mass spectrometry
UPLC: liquid chromatography
XRD: x-ray diffraction
XRF: x-ray fluorescence
XPS: x-ray photoelectron spectroscopy

Supplementary Material
Supplementary figures and tables.
http://www.thno.org/v10p0630s1.pdf
Supplementary videos.
http://www.thno.org/v10p0630s2.mp4
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